© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression
August 07, 2025
Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.
GLP-1 Medications Need a Permanent Place in Primary Care, Says Obesity Medicine Specialist
August 07, 2025
Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.
Use of Weight-Loss Drugs Increased Among US Adolescents After AAP Guideline Release
August 07, 2025
New data shows pediatric pharmacotherapy prescribing rose but remained infrequent, while nutrition counseling rates changed minimally.
Lilly's Oral GLP-1 Agonist Orforglipron Linked to Weight Reduction of 12.4% in Pivotal Phase 3 Trial
August 07, 2025
The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.
Reframing Vaccines as Innovation: A Strategy to Rebuild Patient Trust in Primary Care
August 07, 2025
Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.
Study Sheds Light on Public Perception of Physicians Who Use AI: Daily Dose
August 07, 2025
Your daily dose of the clinical news you may have missed.
Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years
August 06, 2025
Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.
11 US Vaccine Policy Updates: How Will They Affect Your Practice?
August 06, 2025
Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.
Investigational Antidepressant BH-200 Shows Benefit in Phase 2b Trial for MDD
August 06, 2025
The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.